Cambrian Biopharma

The University of Texas MD Anderson Cancer Center and US/UK biotech Replay announced on 14 February that they are launching a new company, Syena, to advance research conducted at the cancer center o

What kinds of biotech companies are able launch offerings on the public markets and what means they use to do so are likely to see some significant changes in 2023 as investors become more judicious a

Germany’s BI Licenses Tumor-Specific Antibodies From Singapore Lab Boehringer Ingelheim GmbH and Singapore’s Agency for Science, Technology and Research (A*STAR) unveiled a global licensing agreem

The global non-profit Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), which provides funding and other support for early-stage development of treatments, diagnostics an